Early renal and vascular changes in ADPKD patients with low-grade albumin excretion and normal renal function

Pablo J. Azurmendi1, Adriana R. Fraga1, Felicita M. Galan1,*, Carol Kotliar2, Elvira E. Arrizurieta1, Marta G. Valdez1, Pedro J. Forcada2, Jose S. Santelha Stefan1 and Rodolfo S. Martin1,2

1Instituto de Investigaciones Médicas Alfredo Lanari, Universidad de Buenos Aires and 2Hospital Universitario Austral, Universidad Austral, Argentina

Correspondence and offprint requests to: Pablo Javier Azurmendi; E-mail: pazurmendi@lanari.fmed.uba.ar
*Deceased.

Abstract

Background. Autosomal dominant polycystic kidney disease (ADPKD) shows an increase in both urine monocyte chemoattractant protein-1 (MCP-1) and carotid intima–media thickness (CIMT) before changes in serum creatinine concentration. Although microalbuminuria is an index of disease progression, data on whether renal alterations and vascular remodelling are already present at normal or minimally increased levels of urine albumin excretion in early stages of the disease are lacking.

Methods. Forty-eight ADPKD patients (24.8 ± 0.8 years) with normal renal function (MDRD 108.1 ± 3.1 ml/min) and 21 age-matched controls were studied in a cross-sectional study. The urine albumin/creatinine ratio (UACR) above the upper range of controls (6.8 mg/g) was taken as the predictor of renal alterations and vascular remodelling. Urine MCP-1, MCP-1 fractional excretion (FE MCP-1), endothelial-dependent vascular relaxation (EDVR), aortic pulse-wave velocity (Ao-PWV) and CIMT were chosen as biomarkers.

Results. No differences between ADPKD with UACR ≤6.8 mg/g and controls were observed in urine MCP-1 (77.7 ± 13.9 versus 57.8 ± 6.3 ng/g), FE MCP-1 (91 ± 19 versus 74 ± 8%), and CIMT (0.47 ± 0.06 versus 0.44 ± 0.07 mm), respectively. Conversely, ADPKD with UACR >6.8 mg/g showed values that were different from the two other groups. In addition, patients with UACR >6.8 and <20 mg/g showed greater values for urine MCP-1, FE MCP-1 and CIMT (131.8 ± 21.7 ng/g, 159 ± 31% and 0.55 ± 0.05 mm, respectively), as compared with patients with UACR ≤6.8 mg/g. The same pattern was found in a subset of normotensive ADPKD patients. No differences were found in EDVR and Ao-PWV.

Conclusion. In young ADPKD patients, normal levels of UACR suggest that renal interstitium is comparable to that in healthy subjects and indicate an absence of subtle atherosclerotic changes in the carotid arteries. Likewise, early renal and vascular changes may be present at UACR below the levels defined as microalbuminuria.

Keywords: albuminuria; autosomal dominant polycystic kidney disease; carotid intima–media thickness; endothelial-dependent vascular relaxation; monocyte chemoattractant protein-1

Introduction

Autosomal dominant polycystic kidney disease (ADPKD) is the most common Mendelian hereditary kidney disorder, responsible for ~7% of dialysis patients in Argentina [1]. After a long phase of arterial hypertension and microalbuminuria, there appears a rather abrupt and relentless fall of kidney function, leading to end-stage renal disease in >50% of patients [2,3]. Whereas monitoring of disease progression through glomerular filtration rate (GFR) changes is well established, few studies have dealt with the clinical significance of renal and vascular markers in early phases of the disease. Thus, Cowley et al. found increased expression of monocyte chemoattractant protein-1 (MCP-1) in a rat model of ADPKD [4]. This was followed by the demonstration of augmented urinary excretion of MCP-1 in adult patients with ADPKD before appreciable increases in serum creatinine or total urinary protein excretion [5]. In addition, numerous reports have established that microalbuminuria is a frequent sign of the disease, associated with cardiovascular manifestations and progressive renal failure [6–8]. More recently, altered intima–media thickness of carotid arteries (CIMT), impaired endothelial-dependent vascular relaxation (EDVR) and ultrasound-defined changes in cardiac structures have been reported in normotensive ADPKD patients as well [8–11]. However, no studies have been designed to early assess the meaning of higher levels of albuminuria within the normal range and to explore the systemic nature of the disease. One approach is to look for the association of kidney and vascular markers in a single population of ADPKD patients when GFR is still normal.

We report here a novel relationship among urine albumin excretion (UAE), urine MCP-1 and vascular structure in a cross-sectional study of young ADPKD patients with
normal renal function. The results suggest that normal UA CR as seen in healthy controls is a predictor of normal renal and vascular status and that increased UA CR below microalbuminuric levels may be associated with early manifestations of the disease.

Methods

Patient selection

Both ADPKD Caucasian patients with no associated renal disease and controls were recruited at the Instituto de Investigaciones Médicas Alfredo Lanari of Universidad de Buenos Aires and Hospital Universitario Austral of Universidad Austral, Buenos Aires, Argentina, during 2005 through 2007. The protocol was approved by the IRB of both institutions, and each subject gave written informed consent. Inclusion criteria were age below 35 years and independently of blood pressure status, absence of overt proteinuria and estimated GFR > 80 ml/min/1.73 m², as given by the abbreviated MDRD equation [12]. ADPKD was diagnosed by ultrasound, according to established criteria [13].

Study protocol

We used a cross-sectional design that compared the magnitude of UA CR with renal and vascular profiles in ADPKD patients. The cut-off for the urine albumin/urine creatinine ratio (UACR) of 6.8 mg/g was taken from the upper limits of age-matched healthy controls. We defined two broad categories of UA CR: normal UACR (non-detectable to < 6.8 mg/g) and increased UACR (≥ 6.8 mg/g). In addition, patients with higher levels of albuminuria within the normal range (UACR > 6.8–< 20 mg/g) were classified as intermediate UA CR. The rationale of this approach rests on the increasing association between intermediate UA CR levels and cardiovascular events in vascular non-diabetic disorders [14–16]. Urine MCP-1 and fractional excretion of MCP-1 (FE_MCP-1) were considered as outcomes of renal status, and CIMT, EDVR of the brachial artery and aortic pulse-wave velocity (Ao-PWV) as vascular markers. To avoid hyperviscosity as a potential confounder, a subset of ADPKD patients with normal blood-pressure (BP) was separately analysed. Normal BP was defined as office registers < 140/90 mmHg and/or diurnal average of 24-h BP monitoring (SPACELAB 90217, Isquaquah, WA, USA) < 135/85 mmHg, with no antihypertensive treatment.

Biochemical parameters

Fasting blood samples were taken under disodic citrate 3.5% for MCP-1 and frozen at −20 °C after centrifugation. Fresh early morning midstream urine specimens were collected, in women in the middle of the menstrual cycle. Microscopy of the urinary sediment was immediately performed under a high-power field (×400) [17]. Urine was titrated if necessary to pH 6–8, and supernatants were frozen at −20 °C until albumin and MCP-1 assays were obtained. UA CR was measured with a competitive chemiluminescent enzyme immunoassay (Immule/Immule 1000 Albumin, DPC, Los Angeles, CA, USA). The calibration range was 2.5–60 μg/ml, and the analytical sensitivity was 1.0 μg/ml. In our laboratory, the coefficient of variation (CV) was 4.0 and 6.5% at 4.0 and 51.0 μg/ml, respectively, and the recovery was 98 ± 5% (mean ± SEM, n = 3). Plasma and urine MCP-1 were measured by an enzyme-linked immunosorbent assay using methods recommended by the manufacturer (Biosource International, Amarillo, CA, USA), as already described [5]. The sensitivity was 20 pg/ml, and the recovery was 110 ± 7% (mean ± SEM, n = 5). Urine MCP-1 was expressed as ng/g of urine creatinine, and FE_MCP-1 was estimated by (urine MCP-1/serum MCP-1)/urine creatinine/plasma creatinine × 100. The total urinary protein was determined with a quantitative colormetric method based on the use of pyrogallol red (Proti Ul/CR, Wiener lab, Rosario, Argentina) using procedures recommended by the manufacturer. The sensitivity was 1 mg/dl, and the standard curve was lineal up to 125 mg/dl. The inter-assay CV was 6.3 and 4.6% at 6.25 and 50 mg/dl, respectively. Results were expressed in mg/g urinary of creatinine. To test tubular protein reabsorption, α1- microglobulin in the urine was quantified by the immunoturbidimetric method with a Tina-Quant α1-microglobulin kit (Cobas Integra, Roche Diagnostics GmbH, Manheim, Germany) using the Architect ci8200 (Abbott Diagnostics, IL, USA). The sensitivity was 2.0 mg/l and the standard curve was lineal up to 200 mg/dl. The CV was 6% at 17 mg/dl. Values were expressed as mg/g urine creatinine. Plasma and urine creatinine were determined by the alkaline picate colorimetric assay. For the vascular studies, subjects abstained from smoking and exercise, fasted for 12 h before testing and without medication, were kept in a quiet room and in a supine position for 10 min. An echocardiograph Vivid 5 (GE/VingMed Ultrasound, Norway) with a multiple linear array 10 MHz flat transducer was used. CIMT was measured according to ASE guidelines in a well-defined wall segment of the posterior wall of the common carotid artery, 1 cm below the carotid bulb [18]. Sequential intra-observer measurements showed a correlation coefficient > 0.8. Values for each patient were expressed in millimetres and represented the mean between left- and right-carotid artery measurements. EDVR and Ao-PWV determinations were performed according to international guidelines [19,20]. Thirty ADPKD patients and 14 controls accepted to participate in the protocol for vascular studies.

Statistical analysis

Assuming a clinically relevant mean difference between groups of 470 pg/mg and 0.13 mm in both urine MCP-1 and CIMT, with an average SD of 420 pg/mg and 0.12 mm, respectively [5,10], we needed 15 cases in each group to obtain 80% power and 5% significance. Biochemical and anthropometrical values are presented as means ± SEM of the disease.

Table 1. Baseline characteristics

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Controls (n = 21)</th>
<th>ADPKD patients (n = 48)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>26.4 ± 1.0</td>
<td>24.8 ± 0.8</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>21.8 ± 0.7</td>
<td>22.6 ± 0.5</td>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>12/9</td>
<td>22/26</td>
</tr>
<tr>
<td>Hypertensive/normotensive</td>
<td>0/21</td>
<td>20/28*</td>
</tr>
<tr>
<td>GFR estimated by MDRD*</td>
<td>111.1 ± 6.1</td>
<td>108.1 ± 3.1</td>
</tr>
<tr>
<td>(ml/min/1.73 m²)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Modification of Diet in Renal Disease. Data are mean ± SE.
*P < 0.001 versus controls.

Results

Patients’ characteristics

As shown in Table 1, 48 young patients and 21 healthy controls, with a mean age of ~25 years, were the basis of this study. They did not differ in BMI, sex and estimated GFR. A higher proportion of mild hypertension was present in the ADPKD group (~42%).

Relationship between UA CR, urine MCP-1 and CIMT

Figure 1 shows that in the ADPKD group with normal UA CR (n = 22), urine MCP-1 (77.7 ± 13.9), FE_MCP-1 (91.9 ± 19) and CIMT (0.47 ± 0.06) were not different from controls (57.8 ± 6.3 mg/g, 74 ± 8% and 0.44 ± 0.07 mm, respectively). Conversely, patients with increased UA CR (25.2 ± 4.0 mg/g, n = 26) showed higher figures than the two other groups (214.8 ± 46.5 mg/g, 278 ± 86% and 0.56 ± 0.07 mm, respectively) (Figure 1), (unadjusted P < 0.005, P < 0.04 and P < 0.01, respectively). In addition, urine
MCP-1, FE\textsubscript{MCP-1} and CIMT were higher in the group with intermediate UACR \((n = 13)\), as compared with patients with normal UACR \((n = 22)\) (Table 2). To assess the role of hypertension, patients with normal and high BP were compared (Table 3). Figure 2 shows that increased UACR in normotensive ADPKD patients was also accompanied by higher values of the chemokine, FE\textsubscript{MCP-1} and CIMT. The same pattern was observed in hypertensive patients (Figure 2), but those with normal UACR were \(~\sim\)4 years younger than the group with increased UACR (Table 3), precluding a final analysis of the role of BP on albumin excretion in the hypertensive group. Overall, the results suggest that high levels of albuminuria below the cut-off point for microalbuminuria are early markers of renal and vascular alterations in ADPKD, independently of BP status.

**Total urine protein and \(\alpha_1\)-microglobulin in urine**

The total urine protein was not different among all ADPKD patients and controls \((45.9 \pm 4.3 \text{ and } 46.5 \pm 4.3 \text{ mg/g})\) as already observed by others \cite{5}; in addition, the total urine protein was not different between patients with increased UACR and normal UACR \((53.9 \pm 4.2 \text{ and } 41.2 \pm 7.4 \text{ mg/g})\). Urinary \(\alpha_1\)-microglobulin was detected in one \((4.6 \text{ mg/g})\) out of 21 controls and one \((4.3 \text{ mg/g})\) out of 48 patients, suggesting an intact protein tubular reabsorption.

**EDVR and Ao-PWV**

EDVR of the brachial artery was \(12.5 \pm 8.9\%\) in ADPKD patients and \(14.2 \pm 8.0\%\) in controls \((P\ N.S.)\). Similar results were observed for Ao-PWV \((6.6 \pm 1.6 \text{ and } 7.1 \pm 2.6 \text{ m/s, respectively})\). Lastly, values for EDVR and Ao-PWV were not related to either UACR or BP status. These observations would thus indicate that the increase observed in CIMT was not accompanied with evident damage in EDVR and Ao-PWV in the groups of patients studied here, even when considering the hypertension effect.

**Discussion**

We present here, in a young ADPKD cohort with normal renal function, novel data on the association of UACR

![Graph](image_url)

**Fig. 1.** Urinary excretion of MCP-1, FE\textsubscript{MCP-1} and carotid intima–media thickness in ADPKD patients and controls, according to urine albumin. Abbreviations: UACR is the urine albumin/creatinine ratio (mg/g). Data are mean \(\pm\) SE for urine monocyte chemoattractant protein (MCP-1) (panel A) and fractional excretion of MCP-1 (FE\textsubscript{MCP-1}) (panel B). Data are mean \(\pm\) SD for carotid intima–media thickness (CIMT) (panel C). Normal UACR (from non-detectable to \(\leq 6.8\)) and increased UACR (>6.8 mg/g). \(*P < 0.05\) versus ADPKD patients with normal UACR and controls.

<table>
<thead>
<tr>
<th>Renal and vascular markers</th>
<th>ADPKD Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Normal UACR ((n = 22))</td>
</tr>
<tr>
<td>MCP-1(^a) (ng/g)</td>
<td>77.7 (\pm) 13.9 (22)*</td>
</tr>
<tr>
<td>FE\textsubscript{MCP-1}(^b) (%)</td>
<td>91 (\pm) 19 (22)*</td>
</tr>
<tr>
<td>CIMT (mm)</td>
<td>0.47 (\pm) 0.06 (14)*</td>
</tr>
</tbody>
</table>

UACR is the urine albumin/creatinine ratio (mg/g). Data are mean \(\pm\) SE for \(^a\)monocyte chemoattractant protein, \(^b\)urine fractional excretion of MCP-1 and means \(\pm\) SD for \(^c\)carotid intima–media thickness.

Normal UACR (from non-detectable to \(\leq 6.8\)), intermediate UACR (>6.8 – \(\leq 20\)), microalbuminuria (>20 mg/g).

\(*P < 0.04\) versus ADPKD patients with intermediate UACR and microalbuminuria.

\(**P < 0.04\) versus ADPKD patients with microalbuminuria.

\cite{48x744}
Table 3. Baseline characteristics of ADPKD patients according to levels of urine albumin and blood pressure (BP) status

<table>
<thead>
<tr>
<th>Characteristics of patients</th>
<th>Normal BP</th>
<th>Increased UACRa (n = 12)</th>
<th>Increased UACRa (n = 16)</th>
<th>High BP</th>
<th>Normal UACRa (n = 9)</th>
<th>Increased UACRa (n = 11)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>25.2 ± 1.2</td>
<td>25.2 ± 1.3</td>
<td>22.7 ± 1.2</td>
<td>26.6 ± 1.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>21.1 ± 0.5</td>
<td>23.5 ± 1.4</td>
<td>23.6 ± 0.8</td>
<td>21.9 ± 0.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>5/7</td>
<td>4/12</td>
<td>6/3</td>
<td>7/4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean blood pressure (mmHg)</td>
<td>92.1 ± 2.99</td>
<td>93.2 ± 2.45</td>
<td>98.9 ± 5.86</td>
<td>105.1 ± 5.97</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GFR estimated by MDRDb (ml/min/1.73 m²)</td>
<td>110.5 ± 4.4</td>
<td>101.0 ± 6.1</td>
<td>98.9 ± 5.86</td>
<td>105.1 ± 5.97</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

aUACR is the urine albumin/creatinine ratio (mg/g), bModification of Diet in Renal Disease. Data are mean ± SE. Normal UACR (from non-detectable to ≤6.8), increased UACR (>6.8 mg/g). *P < 0.05 versus high BP patients with increased UACR.

<6.8 mg/g with an unaltered renal interstitium and an absence of subtle atherosclerotic changes in the carotid arteries. Likewise, we have found a relationship between urine MCP-1, CIMT and increased UACR, even below the levels classically defined as microalbuminuria. Thus, ADPKD patients with increased UACR have not only higher urine MCP-1 excretion than controls and patients with normal UACR (Figure 1A) but also a FE MCP-1 higher than 200% (Figure 1B). The data agree with the report of Zheng et al., who presented strong evidence that MCP-1 generates within the tubule cells and is secreted into the urine. In that study, however, albumin excretion was not explored, and no relationship between the total urinary protein and urine MCP-1 was found in patients with serum creatinine <1.5 mg/dl [5]. In the current study, no association between the total urinary protein and urine chemokine or between the total urinary protein and UAE was found either. This unexpected finding might be explained, at least in part, by the lower analytical sensitivity of the method employed here to measure the total protein (1.0 mg/dl), as compared with that of albumin (1.0 µg/ml).

Taken together, these observations suggest that UAE and not the total urinary protein is a reliable marker for urine MCP-1 and hence of early renal interstitial inflammation.

The clinical value of microalbuminuria in ADPKD, defined as UACR ≥20 mg/g, is well established. Chapman et al. have demonstrated that both overt proteinuria and microalbuminuria were associated with higher mean arterial pressure, lower GFR, larger renal volume and a more aggressive course of the renal disease [6]. Later on, a high prevalence of microalbuminuria was found in normotensive adults and children with ADPKD [7,21], associated with the echocardiographic features of a pre-hypertensive state [8,10]. It seemed appropriate, therefore, to explore whether intermediate UACR between 6.8 and 20 mg/g was associated with subtle manifestations of the disease. We were able to detect in this group higher values for urine MCP-1, FE MCP-1 and CIMT, as compared with patients with normal UACR (Table 2). Furthermore, urine MCP-1 increased with urine albumin along the three UACR levels studied. These results suggest, together with the finding in non-ADPKD individuals who are non-diabetic and at high cardiovascular risk (15, 16), that the definition of normal albumin excretion should be reevaluated at the early stages of ADPKD.
Table 4. Vascular studies in controls and ADPKD according to levels of urine albumin and blood pressure (BP) status

<table>
<thead>
<tr>
<th>Vascular measurements</th>
<th>Controls (n = 14)</th>
<th>Normal UACR* (n = 7)</th>
<th>Increased UACR* (n = 11)</th>
<th>ADPKD high BP</th>
</tr>
</thead>
<tbody>
<tr>
<td>CIMTb (mm)</td>
<td>0.44 ± 0.07</td>
<td>0.49 ± 0.05</td>
<td>0.55 ± 0.05*</td>
<td>0.47 ± 0.06</td>
</tr>
<tr>
<td>EDVRc (%)</td>
<td>14.2 ± 8.0</td>
<td>14.7 ± 10.0</td>
<td>15.9 ± 7.0</td>
<td>6.38 ± 6.6</td>
</tr>
<tr>
<td>Ao-PWVd (m/s)</td>
<td>7.1 ± 2.6</td>
<td>6.9 ± 1.6</td>
<td>6.8 ± 1.1</td>
<td>6.12 ± 1.6</td>
</tr>
</tbody>
</table>

*UACR is the urine albumin/creatinine ratio (mg/g), bcarotid intima–media thickness, cendothelial-dependent vascular relaxation, d aortic pulse-wave velocity.

Data are mean ± SD.

Normal UACR (from non-detectable to < 6.8 mg/g), increased UACR (> 6.8 mg/g).

*P < 0.05 versus ADPKD with normal UACR and control groups.

Our finding of a similar relationship between UACR and CIMT (Figure 1C), independently of BP status and together with a high urine MCP-1, also has no precedent. A previous study also described an increase in CIMT in a normotensive ADPKD population ~ 10 years older than the one presented here, with no mention of urinary albumin excretion [10]. Of interest, UACR and CIMT revealed a parallel increase, with CIMT values levelling off unexpectedly at microalbuminuric levels (Table 2). Whether this dissociation was due to the low number of patients in this group or to an effect of antihypertensive drugs cannot be differentiated in the present study. Taken together, the presence of a significant increase in CIMT in normotensive patients with ADPKD may reflect not only an increased risk of cardiovascular disease but may also be an indicator of concomitant renal interstitial inflammation and cyst growth.

Since microalbuminuria has been classically associated with BP status, both in non-ADPKD and ADPKD populations, there is the question whether the increase in both the chemokine and CIMT observed here were caused by arterial hypertension. Previous data of Kocaman et al. [10] and of the present study in normotensive patients (Table 3 and Figure 2) suggest that the concomitant renal and vascular changes are intrinsic to ADPKD. A further analysis of GFR in the different groups given in Table 3 is precluded by the fact that the MDRD equation underestimates GFR by ~ 8.3 ml/min/1.73 m² and is less accurate in populations with normal or near normal GFR [22].

Since increased urine albumin may be the consequence of endothelial dysfunction and abnormal vascular permeability, the changes found in our study may be mediated by such a mechanism. Alternatively, since polycystins have been tracked down to vascular smooth muscle cell structures and the cilia of endothelial cells [23,24], vascular events cannot be excluded as a primary phenotype of the disease.

We were not able to find a decreased EDVR of the brachial artery, not even in the subset of normotensive patients (Table 4), which suggests that an intact NO-dependent relaxation of conduit arteries was present in our patients. Our results are thus compatible with previous data where preserved EDVR and impaired amplified pulse-wave reflection were found, supporting the role of small resistance arteries in the vascular phenotype of ADPKD [25–27]. Data from a previous report where EDVR was diminished should be interpreted as an altered smooth muscle response, as shown in the endothelial-independent relaxation results [10]. Lastly, Ao-PWV was unchanged in our study, which agrees with a recent observation [27], indicating that viscous and elastic components of great blood vessels were not altered at the early stages of the disease.

Increased UAE may be the consequence, at least in part, of decreased albumin re-uptake at a tubular level. We measured here urine α₁-microglobulin, a protein that is freely filtered and reabsorbed at proximal tubular level. α₁-microglobulin was not increased above the control limits in ADPKD patients, in accordance with a previous report [28]. Although additional tubular markers have been found to be increased in ADPKD [29], a tubular mechanism seems to play a minor role in the increased UAE observed in ADPKD.

In summary, our study mainly showed that urinary albumin excretion in the range of a normal population predicts a renal interstitium comparable to that of healthy subjects and absence of vascular remodelling in young ADPKD patients with normal renal function. In addition, it suggests that low grade UAE, below the levels defined as microalbuminuria, is already associated with early pathological processes at renal and vascular levels. Whether the variables measured here could eventually be used as markers of disease progression is a hypothesis that needs further longitudinal exploration.

Acknowledgments. Part of the data were presented as Abstract at the ‘07 World Congress of Nephrology, Rio de Janeiro, Brazil and ISN Forefronts Symposium on PKD, Montreal, 2008. We thank Valeria Argázarce, Cecilia Blanco, Karina de Mateis, Marcela Pagano and Mercedes Rojas for helpful assistance. This work was supported by a grant from National Agency for Scientific Research, Argentina, BID 1201/OC-ARPICT 13630 and a grant of Austral University (Res. N° 268/05).

Conflict of interest statement. C.K. is involved in trials with Takeda-Novartis and Gilead. P.F. is the medical advisor of Servier. R.M. is PI in a phase III study on the use of Tolvaptan in ADPKD. Other authors have nothing to declare.

References

de síntasa endotelial del óxido nítrico (ecNOS) y del sistema renina angiotensina. *Medicina (Buenos Aires)* 2004; 64: 139–142

Received for publication: 19.6.08; Accepted in revised form: 26.1.09